|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 0.3119 USD | -6.48% |
|
-2.65% | -68.81% |
| 09-02 | Needham Downgrades TScan Therapeutics to Hold From Buy | MT |
| 09-02 | Wedbush Downgrades TScan Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $5 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 22.6M | - | - | |||
| 70.89B | |||||
| 62.32B | |||||
| 27.07B | - | ||||
| 26.2B | |||||
| 24.78B | - |
Select your edition
All financial news and data tailored to specific country editions
